New hope for hemophilia patients whose bodies fight treatment

NCT ID NCT04023019

Summary

This study aims to understand the best ways to treat people with hemophilia A whose immune systems have developed 'inhibitors' that block standard treatments. Researchers will observe 120 male participants for up to 5 years as they receive different combinations of immune tolerance therapy and newer medications to control bleeding. The goal is to compare how well these approaches work to reduce inhibitors, control bleeds, and improve safety.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEMOPHILIA A are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Arthur M. Blank Hospital

    RECRUITING

    Atlanta, Georgia, 30329, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • HZRM Hämophilie-Zentrum Rhein Main

    RECRUITING

    Mörfelden-Walldorf, 64546, Germany

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.